Tacrine

Add time:09/26/2019    Source:sciencedirect.com

In the early 1950s, tacrine was used experimentally to reverse cholinergic coma in animals. In 1993, the US Food and Drug Administration approved tacrine for the treatment of mild to moderate Alzheimer's disease. Tacrine causes reversible acetylcholinesterase inhibition in the brain, and thereby boosts the level of acetylcholine to sustain memory. In addition, tacrine blocks sodium and potassium channels. At a therapeutic dose, tacrine causes liver toxicity. Tacrine-induced hepatotoxicity is due to oxidative stress. Treatment rests with use of atropine, antioxidants, and other symptomatic measures. Tacrine is no longer indicated for Alzheimer's treatment.

We also recommend Trading Suppliers and Manufacturers of TACRINE HYDROCHLORIDE (cas 1684-40-8). Pls Click Website Link as below: cas 1684-40-8 suppliers

Prev:Solid-state characterization of TACRINE HYDROCHLORIDE (cas 1684-40-8)
Next:Novel tacrine-coumarin hybrids linked to 1,2,3-triazole as anti-Alzheimer’s compounds: In vitro and in vivo biological evaluation and docking study)